Literature DB >> 29884728

An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Rong Lu1,2, Payal Kapur3,4, Bijay S Jaiswal5, Tao Wang6,3,7, Raquibul Hannan3,8, Ze Zhang1, Ivan Pedrosa3,9, Jason J Luke10, He Zhang2, Leonard D Goldstein5, Qurratulain Yousuf3,11, Yi-Feng Gu3,11, Tiffani McKenzie3, Allison Joyce3,11, Min S Kim3,2, Xinlei Wang12, Danni Luo2, Oreoluwa Onabolu3,11, Christina Stevens3,11, Zhiqun Xie1, Mingyi Chen4, Alexander Filatenkov4, Jose Torrealba4, Xin Luo2, Wenbin Guo1, Jingxuan He1, Eric Stawiski5,13, Zora Modrusan5, Steffen Durinck5,13, Somasekar Seshagiri14, James Brugarolas15,11.   

Abstract

By leveraging tumorgraft (patient-derived xenograft) RNA-sequencing data, we developed an empirical approach, DisHet, to dissect the tumor microenvironment (eTME). We found that 65% of previously defined immune signature genes are not abundantly expressed in renal cell carcinoma (RCC) and identified 610 novel immune/stromal transcripts. Using eTME, genomics, pathology, and medical record data involving >1,000 patients, we established an inflamed pan-RCC subtype (IS) enriched for regulatory T cells, natural killer cells, TH1 cells, neutrophils, macrophages, B cells, and CD8+ T cells. IS is enriched for aggressive RCCs, including BAP1-deficient clear-cell and type 2 papillary tumors. The IS subtype correlated with systemic manifestations of inflammation such as thrombocytosis and anemia, which are enigmatic predictors of poor prognosis. Furthermore, IS was a strong predictor of poor survival. Our analyses suggest that tumor cells drive the stromal immune response. These data provide a missing link between tumor cells, the TME, and systemic factors.Significance: We undertook a novel empirical approach to dissect the renal cell carcinoma TME by leveraging tumorgrafts. The dissection and downstream analyses uncovered missing links between tumor cells, the TME, systemic manifestations of inflammation, and poor prognosis. Cancer Discov; 8(9); 1142-55. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1047. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29884728      PMCID: PMC6125163          DOI: 10.1158/2159-8290.CD-17-1246

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  47 in total

1.  Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma.

Authors:  Hangcheng Fu; Yu Zhu; Yiwei Wang; Zheng Liu; Junyu Zhang; Zewei Wang; Huyang Xie; Bo Dai; Jiejie Xu; Dingwei Ye
Journal:  Ann Surg Oncol       Date:  2016-11-28       Impact factor: 5.344

2.  Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Authors:  Stefani Spranger; Jason J Luke; Riyue Bao; Yuanyuan Zha; Kyle M Hernandez; Yan Li; Alexander P Gajewski; Jorge Andrade; Thomas F Gajewski
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

3.  Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.

Authors:  A Napolitano; L Pellegrini; A Dey; D Larson; M Tanji; E G Flores; B Kendrick; D Lapid; A Powers; S Kanodia; S Pastorino; H I Pass; V Dixit; H Yang; M Carbone
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

4.  Immunotherapy for renal cell carcinoma.

Authors:  Momoe Itsumi; Katsunori Tatsugami
Journal:  Clin Dev Immunol       Date:  2011-01-03

5.  Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas.

Authors:  Masahiro Yao; Takayuki Murakami; Koichi Shioi; Nobuhiko Mizuno; Hiroki Ito; Keiichi Kondo; Hisashi Hasumi; Futoshi Sano; Kazuhide Makiyama; Noboru Nakaigawa; Takeshi Kishida; Yoji Nagashima; Shoji Yamanaka; Yoshinobu Kubota
Journal:  Cancer Med       Date:  2014-05-26       Impact factor: 4.452

6.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

Review 7.  Renal cell carcinoma.

Authors:  Eric Jonasch; Jianjun Gao; W Kimryn Rathmell
Journal:  BMJ       Date:  2014-11-10

8.  Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Authors:  Gülçin Gezgin; Mehmet Dogrusöz; T Huibertus van Essen; Wilhelmina G M Kroes; Gregorius P M Luyten; Pieter A van der Velden; Vonn Walter; Robert M Verdijk; Thorbald van Hall; Sjoerd H van der Burg; Martine J Jager
Journal:  Cancer Immunol Immunother       Date:  2017-04-08       Impact factor: 6.968

9.  Fibroblast activation protein (FAP) is essential for the migration of bone marrow mesenchymal stem cells through RhoA activation.

Authors:  Kuei-Min Chung; Shu-Ching Hsu; Yue-Ru Chu; Mei-Yao Lin; Weir-Tong Jiaang; Ruey-Hwa Chen; Xin Chen
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

Review 10.  Immunotherapy of melanoma.

Authors:  John B A G Haanen
Journal:  EJC Suppl       Date:  2013-09
View more
  55 in total

1.  Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.

Authors:  A Ari Hakimi; Martin H Voss; Fengshen Kuo; Alejandro Sanchez; Ming Liu; Briana G Nixon; Lynda Vuong; Irina Ostrovnaya; Ying-Bei Chen; Victor Reuter; Nadeem Riaz; Yuan Cheng; Parul Patel; Mahtab Marker; Albert Reising; Ming O Li; Timothy A Chan; Robert J Motzer
Journal:  Cancer Discov       Date:  2019-01-08       Impact factor: 39.397

2.  Bayesian multiple instance regression for modeling immunogenic neoantigens.

Authors:  Seongoh Park; Xinlei Wang; Johan Lim; Guanghua Xiao; Tianshi Lu; Tao Wang
Journal:  Stat Methods Med Res       Date:  2020-05-13       Impact factor: 3.021

3.  Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.

Authors:  Britney Reese; Ashok Silwal; Elizabeth Daugherity; Michael Daugherity; Mahshid Arabi; Pierce Daly; Yvonne Paterson; Layton Woolford; Alana Christie; Roy Elias; James Brugarolas; Tao Wang; Magdalena Karbowniczek; Maciej M Markiewski
Journal:  J Immunol       Date:  2020-11-06       Impact factor: 5.422

4.  Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis.

Authors:  Jun Nishida; Yusaku Momoi; Kosuke Miyakuni; Yusuke Tamura; Kei Takahashi; Daizo Koinuma; Kohei Miyazono; Shogo Ehata
Journal:  Nat Cell Biol       Date:  2020-03-23       Impact factor: 28.824

5.  Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.

Authors:  Tianshi Lu; Shidan Wang; Lin Xu; Qinbo Zhou; Nirmish Singla; Jianjun Gao; Subrata Manna; Laurentiu Pop; Zhiqun Xie; Mingyi Chen; Jason J Luke; James Brugarolas; Raquibul Hannan; Tao Wang
Journal:  Sci Immunol       Date:  2020-02-21

6.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

Authors:  David J Clark; Saravana M Dhanasekaran; Francesca Petralia; Jianbo Pan; Xiaoyu Song; Yingwei Hu; Felipe da Veiga Leprevost; Boris Reva; Tung-Shing M Lih; Hui-Yin Chang; Weiping Ma; Chen Huang; Christopher J Ricketts; Lijun Chen; Azra Krek; Yize Li; Dmitry Rykunov; Qing Kay Li; Lin S Chen; Umut Ozbek; Suhas Vasaikar; Yige Wu; Seungyeul Yoo; Shrabanti Chowdhury; Matthew A Wyczalkowski; Jiayi Ji; Michael Schnaubelt; Andy Kong; Sunantha Sethuraman; Dmitry M Avtonomov; Minghui Ao; Antonio Colaprico; Song Cao; Kyung-Cho Cho; Selim Kalayci; Shiyong Ma; Wenke Liu; Kelly Ruggles; Anna Calinawan; Zeynep H Gümüş; Daniel Geiszler; Emily Kawaler; Guo Ci Teo; Bo Wen; Yuping Zhang; Sarah Keegan; Kai Li; Feng Chen; Nathan Edwards; Phillip M Pierorazio; Xi Steven Chen; Christian P Pavlovich; A Ari Hakimi; Gabriel Brominski; James J Hsieh; Andrzej Antczak; Tatiana Omelchenko; Jan Lubinski; Maciej Wiznerowicz; W Marston Linehan; Christopher R Kinsinger; Mathangi Thiagarajan; Emily S Boja; Mehdi Mesri; Tara Hiltke; Ana I Robles; Henry Rodriguez; Jiang Qian; David Fenyö; Bing Zhang; Li Ding; Eric Schadt; Arul M Chinnaiyan; Zhen Zhang; Gilbert S Omenn; Marcin Cieslik; Daniel W Chan; Alexey I Nesvizhskii; Pei Wang; Hui Zhang
Journal:  Cell       Date:  2019-10-31       Impact factor: 41.582

Review 7.  Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.

Authors:  Lynda Vuong; Ritesh R Kotecha; Martin H Voss; A Ari Hakimi
Journal:  Cancer Discov       Date:  2019-09-16       Impact factor: 39.397

8.  Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.

Authors:  David A Braun; Kelly Street; Kelly P Burke; David L Cookmeyer; Thomas Denize; Christina B Pedersen; Satyen H Gohil; Nicholas Schindler; Lucas Pomerance; Laure Hirsch; Ziad Bakouny; Yue Hou; Juliet Forman; Teddy Huang; Shuqiang Li; Ang Cui; Derin B Keskin; John Steinharter; Gabrielle Bouchard; Maxine Sun; Erica M Pimenta; Wenxin Xu; Kathleen M Mahoney; Bradley A McGregor; Michelle S Hirsch; Steven L Chang; Kenneth J Livak; David F McDermott; Sachet A Shukla; Lars R Olsen; Sabina Signoretti; Arlene H Sharpe; Rafael A Irizarry; Toni K Choueiri; Catherine J Wu
Journal:  Cancer Cell       Date:  2021-03-11       Impact factor: 31.743

9.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.

Authors:  Robert J Motzer; Romain Banchereau; Habib Hamidi; Thomas Powles; David McDermott; Michael B Atkins; Bernard Escudier; Li-Fen Liu; Ning Leng; Alexander R Abbas; Jinzhen Fan; Hartmut Koeppen; Jennifer Lin; Susheela Carroll; Kenji Hashimoto; Sanjeev Mariathasan; Marjorie Green; Darren Tayama; Priti S Hegde; Christina Schiff; Mahrukh A Huseni; Brian Rini
Journal:  Cancer Cell       Date:  2020-11-05       Impact factor: 31.743

10.  Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform.

Authors:  Durga Udayakumar; Ze Zhang; Yin Xi; Durgesh K Dwivedi; Michael Fulkerson; Sydney Haldeman; Tiffani McKenzie; Qurratulain Yousuf; Allison Joyce; Asghar Hajibeigi; Hollis Notgrass; Alberto Diaz de Leon; Qing Yuan; Matthew A Lewis; Ananth J Madhuranthakam; Robert C Sibley; Roy Elias; Junyu Guo; Alana Christie; Renée M McKay; Jeffrey A Cadeddu; Aditya Bagrodia; Vitaly Margulis; James Brugarolas; Tao Wang; Payal Kapur; Ivan Pedrosa
Journal:  Clin Cancer Res       Date:  2021-07-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.